Company
Every investor coverage indicates participated in a round Monash Institute of Pharmaceutical Sciences raised.
Companies Monash Institute of Pharmaceutical Sciences acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Bernard Flynn | Associate Professor | @AuManufacturing, Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Monash Institute of Pharmaceutical Sciences. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Manufacturing news roundup: GreenHY2 and Atomo Diagnostics receive government grants, Seaport Therapeutics closes a US$225m Series B, Orthocell secures $17m, Genevo Marine opens a crowdfunding offer, and the ACCC clears Accolade's wine acquisition.
Roundup of Australian manufacturing items: Manildra draws on CEFC money to quit coal, Ankere Therapeutics launches with seed backing, Micro-X gear reaches Ukraine, plus a vessel naming, precinct tenders, an FFI appointment and a cable rebrand.
Biotech startup Ankere Therapeutics launches with a $10 million seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies, building on research from Monash and UniSA scientists.
Also Brandon Capital portfolio·Startup Daily·@AuManufacturing